Post by Deleted on Apr 21, 2019 15:30:49 GMT
“The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies…. While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.
"MedPage Today reports that this is indeed a distinct possibility based on fact. Well, if you insist on making a drug that cures with one dose, we would recommend charging a king’s ransom for it. Could we propose that you charge $1 million for a course of treatment? Do you think such a figure is exaggerated? Early this year, Spark Therapeutics introduced its new drug (Luxturna) for a rare form of blindness. It promises a cure with a single dose. The price tag is $425,000 per eye. That means $850,000 for a cure.
And it gets worse. In 2012, a company called uniQure N.V. marketed Glybera (tiparvovec) for the treatment of lipoprotein lipase deficiency at a price of $1.6 million per treatment. After one patient in the entire world was treated, no one seemed excited about prescribing the overpriced drug, and the company did not renew its marketing license.”"
link
"MedPage Today reports that this is indeed a distinct possibility based on fact. Well, if you insist on making a drug that cures with one dose, we would recommend charging a king’s ransom for it. Could we propose that you charge $1 million for a course of treatment? Do you think such a figure is exaggerated? Early this year, Spark Therapeutics introduced its new drug (Luxturna) for a rare form of blindness. It promises a cure with a single dose. The price tag is $425,000 per eye. That means $850,000 for a cure.
And it gets worse. In 2012, a company called uniQure N.V. marketed Glybera (tiparvovec) for the treatment of lipoprotein lipase deficiency at a price of $1.6 million per treatment. After one patient in the entire world was treated, no one seemed excited about prescribing the overpriced drug, and the company did not renew its marketing license.”"
link
